Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 3, 2007, Pages 351-356

  Lin, Peng Chan ^a,b   Chen, Wei Shone ^c   Chao, Ta Chung ^a   Yang, Shung Haur ^c   Tiu, Chui Mei ^c   Liu, Jin Hwang ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Colorectal cancer; Metronomic chemotherapy; Oxaliplatin; Tegafur; UFT

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; SURVIVAL ANALYSIS; TEGAFUR; URACIL;

EID: 34250637586     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0377-4     Document Type: Article

References (32)

1. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group New Engl J Med 343:905-914
2. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Onco 22:229-237
3. de Gramont A, Vignoud J, Tournigand C et al (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219
4. Andre T, Bensmaine MA, Louvet C et al (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568
5. Maindrault-Goebel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005
6. Hsieh RK, Chao TY, Chen WS et al (2004) Oxaliplatin added the simplified bimonthly low dose leucovorin and 5- FU on pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Invest 22:171-179
7. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
8. Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
9. Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886
10. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24
11. Hanahan D, Bergers G, Bergsland E et al (2000) Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047
12. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436
13. Pietras K, Hanahan DA (2005) Multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939-952
14. Miller KD, Sweeney CJ, Sledge GW et al (2005) Refining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206
15. Yonekura K, Basaki Y, Chikahisa L et al (1999) UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5:2185-2191
16. Tanaka F, Yanagihara K, Otake Y et al (2004) Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer. Cancer Sci 95:371-376
17. Rustum YM (1997) Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology (Karger) 1:7-11
18. Maehara Y, Kakeji Y, Ohno S et al (1997) Scientific basis for the combination of tegafur with uracil. Oncology (Huntington) 11:14-21
19. Rougier P (1998) Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 25:23-31
20. Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617-3627
21. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616
22. Saltz LB, Leichman CG, Young CW et al (1995) A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75:782-785
23. Maroun J, Asche C, Romeyer F et al (2003) A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 21:1039-1051
24. Feliu J, Vicent JM, Garcia-Giron C et al (2004) Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer 91:1758-1762
25. Kim K, Nam E, Lee NS et al (2002) Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. Am J Clin Oncol 25:354-357
26. Therasse P, Arbuck SG, Eisenheuer EA et al (2000) New Guide-lines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
27. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
28. de Gramont A, Figer A, Seymour M et al ( 2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol.18:2938-2947
29. Reddy GK (2005) The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin Colorectal Cancer 4:300-301
30. Yoshikawa R, Kusunoki M, Yanagi H et al (2001) Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61:1029-1037
31. Borner MM, Schoffski P, de Wit R et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349-358
32. Fischel JL, Formento P, Ciccolini J et al (2002) Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 86:1162-1168